Evommune (EVMN) Other Accumulated Expenses (2024 - 2026)

Evommune (EVMN) has reported Other Accumulated Expenses for 3 consecutive years, with $571000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $571000.0; the TTM figure through Mar 2026 stood at $571000.0 (changed N/A YoY), while the FY2025 annual figure was $632000.0, up 10.3% from the prior year.
• Other Accumulated Expenses fell to $571000.0 in Q1 2026 per EVMN's latest filing, from $632000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $632000.0 in Q4 2025 and bottomed at $449000.0 in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $556250.0 across 3 years, with a median of $572000.0 in 2024.
• On a YoY basis, Other Accumulated Expenses climbed as much as 10.3% in 2025 and fell as far as 10.3% in 2025.
• Evommune's Other Accumulated Expenses stood at $573000.0 in 2024, then advanced by 10.3% to $632000.0 in 2025, then dropped by 9.65% to $571000.0 in 2026.
• Business Quant data shows EVMN's Other Accumulated Expenses at $571000.0 in Q1 2026, $632000.0 in Q4 2025, and $449000.0 in Q3 2025.